Inhibitor of human myeloid leukemia on base of asymmetric cobalt trichloroacetate dimer

摘要

The invention relates to the application of coordinative combinations in medicine, namely to the use of monohydrate (m-aqua)-bis-(m-trichloroacetato)-tri(aqua)cobalt-aqua-bis-(trichloroacetato)cobalt as inhibitor of human myeloid leukemia.Summary of the invention consists in that as inhibitor of human myeloid leukemia is claimed (m-aqua)-bis-(m-trichloroacetato)-tri(aqua)cobalt-aqua-bis-(trichloroacetato)cobalt monohydrate of the formula:The result of the invention consists in the establishment at the known (m-aqua)-bis-(m-trichloroacetato)-tri(aqua)cobalt-aqua-bis-(trichloroacetato)cobalt monohydrate of the anticancer activity, exceeding 1,25...1,35 times the analogous characteristics of the dimeric trihydrate of aquaethylenediaminetetraacetatobismuthate (III) of 1,6-dimitrotetraaminecobalt (III) and dehydrate of ethylenediaminetetraacetatobismuthate (III) of oxalatotetraaminecobalt (III) (of the analogue).